Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Obesity or Overweight With and Without Type 2 Diabetes (Master Protocol)
NCT06993792Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised trial of orforglipron in obesity and type 2 diabetes mellitus (T2DM) (10 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Allocated to Each Study at 4 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06993792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993792.